Supernus Pharmaceuticals, Inc.
SUPN
$44.88
$1.563.60%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 665.13M | 668.00M | 661.82M | 651.97M | 630.16M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 665.13M | 668.00M | 661.82M | 651.97M | 630.16M |
| Cost of Revenue | 76.27M | 77.36M | 77.91M | 71.44M | 73.45M |
| Gross Profit | 588.85M | 590.64M | 583.91M | 580.54M | 556.71M |
| SG&A Expenses | 351.76M | 343.11M | 335.28M | 334.96M | 336.40M |
| Depreciation & Amortization | 78.34M | 77.63M | 77.98M | 80.80M | 82.56M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 613.09M | 608.89M | 599.96M | 590.69M | 589.53M |
| Operating Income | 52.04M | 59.11M | 61.86M | 61.28M | 40.64M |
| Income Before Tax | 82.16M | 91.80M | 97.87M | 72.48M | 37.42M |
| Income Tax Expenses | 17.67M | 29.88M | 24.01M | 12.77M | 32.19M |
| Earnings from Continuing Operations | 64.50 | 61.91 | 73.87 | 59.71 | 5.24 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 64.50M | 61.91M | 73.87M | 59.71M | 5.24M |
| EBIT | 52.04M | 59.11M | 61.86M | 61.28M | 40.64M |
| EBITDA | 132.72M | 139.16M | 142.27M | 144.53M | 125.64M |
| EPS Basic | 1.16 | 1.12 | 1.34 | 1.08 | 0.09 |
| Normalized Basic EPS | 0.79 | 0.86 | 0.88 | 0.85 | 0.59 |
| EPS Diluted | 1.15 | 1.11 | 1.32 | 1.07 | 0.09 |
| Normalized Diluted EPS | 0.78 | 0.85 | 0.87 | 0.84 | 0.58 |
| Average Basic Shares Outstanding | 222.50M | 221.46M | 220.40M | 219.58M | 219.04M |
| Average Diluted Shares Outstanding | 224.99M | 224.07M | 223.83M | 222.67M | 221.26M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |